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ORIGINAL INVESTIGATION
Machine-learning to stratify diabetic 
patients using novel cardiac biomarkers 
and integrative genomics
Quincy A. Hathaway1,2, Skyler M. Roth3, Mark V. Pinti4, Daniel C. Sprando5, Amina Kunovac1,2, Andrya J. Durr1,2, 
Chris C. Cook6, Garrett K. Fink1, Tristen B. Cheuvront3, Jasmine H. Grossman3, Ghadah A. Aljahli3, 
Andrew D. Taylor1,2, Andrew P. Giromini5, Jessica L. Allen3 and John M. Hollander1,2* 
Abstract 
Background: Diabetes mellitus is a chronic disease that impacts an increasing percentage of people each year. 
Among its comorbidities, diabetics are two to four times more likely to develop cardiovascular diseases. While HbA1c 
remains the primary diagnostic for diabetics, its ability to predict long-term, health outcomes across diverse demo-
graphics, ethnic groups, and at a personalized level are limited. The purpose of this study was to provide a model for 
precision medicine through the implementation of machine-learning algorithms using multiple cardiac biomarkers as 
a means for predicting diabetes mellitus development.
Methods: Right atrial appendages from 50 patients, 30 non-diabetic and 20 type 2 diabetic, were procured from the 
WVU Ruby Memorial Hospital. Machine-learning was applied to physiological, biochemical, and sequencing data for 
each patient. Supervised learning implementing SHapley Additive exPlanations (SHAP) allowed binary (no diabetes or 
type 2 diabetes) and multiple classification (no diabetes, prediabetes, and type 2 diabetes) of the patient cohort with 
and without the inclusion of HbA1c levels. Findings were validated through Logistic Regression (LR), Linear Discrimi-
nant Analysis (LDA), Gaussian Naïve Bayes (NB), Support Vector Machine (SVM), and Classification and Regression Tree 
(CART) models with tenfold cross validation.
Results: Total nuclear methylation and hydroxymethylation were highly correlated to diabetic status, with nuclear 
methylation and mitochondrial electron transport chain (ETC) activities achieving superior testing accuracies in the 
predictive model (~ 84% testing, binary). Mitochondrial DNA SNPs found in the D-Loop region (SNP-73G, -16126C, and 
-16362C) were highly associated with diabetes mellitus. The CpG island of transcription factor A, mitochondrial (TFAM) 
revealed CpG24 (chr10:58385262, P = 0.003) and CpG29 (chr10:58385324, P = 0.001) as markers correlating with dia-
betic progression. When combining the most predictive factors from each set, total nuclear methylation and CpG24 
methylation were the best diagnostic measures in both binary and multiple classification sets.
Conclusions: Using machine-learning, we were able to identify novel as well as the most relevant biomarkers associ-
ated with type 2 diabetes mellitus by integrating physiological, biochemical, and sequencing datasets. Ultimately, 
this approach may be used as a guideline for future investigations into disease pathogenesis and novel biomarker 
discovery.
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Background
A disconnect continues to persist in the diagnosis and 
pathogenesis of diabetes-induced cardiovascular dys-
function. While diabetics are at a two to fourfold greater 
risk of developing cardiovascular diseases [1, 2], under-
standing how the numerous biochemical markers 
involved in the pathology integrate and influence dis-
ease progression has not been fully explicated. In a clini-
cal setting, the ability to better calculate prognostics of 
a patient’s health through the integration of biomarkers 
facilitates the potential for developing personalized and 
generalized medicine, as well as treatment strategies [3]. 
While glycated hemoglobin (HbA1c) remains a hallmark 
for disease diagnosis [4], other biomarkers may exist that 
more unequivocally define the severity of the pathology, 
characterize the mechanisms involved, and/or provide a 
better predictive tool of future cardiovascular events.
Diabetes mellitus is a multifaceted disease, consisting 
of systemic comorbidities which necessitate a variety of 
treatment modalities and stratify those affected with 
the disease [5]. Before the implementation of machine-
learning algorithms in medicine, linear statistical models 
have highlighted measures, such as HbA1c, as diagnos-
tic staples for the evaluation of diabetes mellitus onset 
and progression [6]. By exploring these previously pub-
lished metadata sets, machine-learning has been applied 
in refining the accuracy of biomarkers used to charac-
terize the pathology as well as to highlight vulnerable 
populations in need of clinical intervention [7]. Machine-
learning has also revealed that coupling HbA1c with 
additional biomarkers, such as 8-hydroxy-2-deoxyguano-
sine (8-OhdG) and other metabolites, can increase the 
accuracy of the predictive model and better characterize 
the severity of the disease [8].
In cardiology, machine-learning approaches have been 
applied primarily to imaging-based diagnostics, includ-
ing echocardiography and computed tomography angi-
ography to evaluate cardiovascular health and outcomes 
[9, 10]. It is estimated that machine-learning applications 
in the field of cardiovascular research will continue to 
grow at an exponential rate [11]. While image-derived 
deep learning models are increasing in popularity, little is 
known about the predicative power of machine-learning 
models on basic genomic, epigenomic, proteomic, and 
metabolomic profiles of the heart. While the beginning 
of the “big data” age was characterized by the accumu-
lation and compartmentalization of datasets, the recent 
advent of combining metadata, deep sequencing, and 
“omics”-based approaches warrants the union between 
hierarchical predictive algorithms and biological pro-
cesses. As more patients have access to their personal 
“omics” profiles, machine-learning will be instrumental 
in providing feedback for the individual patient and the 
general population of patients impacted by the disease, 
enhancing health practice by the caregiver.
While demographic information and physical exami-
nation data are more easily procured from patients, the 
genomic and transcriptomic characterization of a tis-
sue or cell type provides a much finer granularity and 
uniqueness when predicting phenotypic outcomes in 
patients [12]. HbA1c, fasting blood glucose, and BMI 
are examples of easily accessible, valuable measurements 
when evaluating diabetes progression and onset [6, 13], 
but genetic components, including epigenetic, epitran-
scriptomic, single nucleotide polymorphisms (SNPs), 
and others, provide a wealth of undiscovered informa-
tion for disease classification. This genetic component 
may be specifically important when understanding the 
pathogenesis of diabetes in ethnic groups, when BMI [14, 
15] and HbA1c [16] show distinct differences between 
ethnicities. Though applying patient-matched, genomic 
information is currently unrealistic for disease diagnosis, 
it may hold the key for revealing commonalities across 
ethnic and demographic groups when classifying diabetic 
onset, progression, and severity.
In the current study, machine-learning was used as a 
predictive tool to integrate cardiac physiological, bio-
chemical, genomic, and epigenomic biomarker data in 
a patient-matched fashion and enable determination of 
type 2 diabetic status. In 50 patients, machine-learning 
algorithms revealed the interconnectedness between dia-
betic classification, mitochondrial function, and methyla-
tion status. Our study highlights how novel biomarkers 
can be used to augment existing diagnostic standards as 
well as provide new, and more precise, methods for iden-
tifying the development and severity of type 2 diabetes 
mellitus in potentially at-risk populations, such as those 
with prediabetes. While we examine physiological, bio-
chemical, and molecular datasets using machine-learning 
algorithms, our goal was to understand which features 
possessed the best predictive accuracies and if these spe-
cific features could be used alone, or in conjunction, with 
HbA1c. The purpose for the inclusion of models that do 
not rise above 50% predictive accuracy was to contrast 
them against those models that do rise above 50% in the 
absence of HbA1c, to determine which biomarkers are 
the best overall predictors.
Research design and methods
Study approval
All tissue and patient information was acquired in a 
double de-identified fashion, and was approved by the 
West Virginia University Institutional Review Board and 
Institutional Biosafety Committee [17]. Patients were all 
consented by the Heart and Vascular Institute, J.W. Ruby 
Memorial Hospital at the West Virginia University School 
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of Medicine. Right atrial appendages were removed dur-
ing open-heart and/or valvular surgeries. Both groups 
of patients (non-diabetic and type 2 diabetic) who were 
receiving open-heart surgery could elect for their tissues 
to be used for research purposes, with no direct or indi-
rect incentivisation. A total of 50 patients were selected 
for the study (between August 2016 and May 2018), 30 
of which were non-diabetic (ND) and 20 that were type 2 
diabetic (T2DM) and existed along a spectrum of meas-
ured HbA1c levels. Patient inclusion into the study was 
determined by (a) election for open heart surgery and 
release of tissue for research purposes (b) was not under-
going surgery due to heart failure, and (c) demographic 
data was provided. Patient characteristics are provided 
in Table 1, listing patients classified as non-diabetic and 
those who have been clinically diagnosed as type 2 dia-
betic. Patient information is also provided for separation 
of the groups into those with no diabetes, prediabetes, 
and type 2 diabetes (Additional file  1: Table  S1). Addi-
tional file  1: Table  S1 contains the matching 50 patient 
cohort analyzed in Table 1 but with the creation of a new 
non-diabetic cohort (n = 16), comprised of those individ-
uals with an HbA1c < 5.7, and prediabetic cohort (n = 14), 
comprised of clinically non-diabetic patients whose 
HbA1c is between 5.7 and 6.4.
Mitochondrial isolation
Mitochondria were isolated from a portion of the right 
atrial appendage as previously described [18], with 
modifications by our laboratory [19–21]. Mitochondrial 
subpopulations of subsarcolemmal and interfibrillar 
mitochondria were extracted and combined to achieve a 
total mitochondrial population.
Electron transport chain (ETC) complex activities
A portion of the tissue from all 50 patients was homog-
enized using a Polytron PowerGen 500 S1 tissue 
homogenizer (Fisher Scientific, Hampton, NH) in NP-40 
buffer (150 mM NaCl, 50 mM, pH 8.0 Tris-Cl, and 1.0% 
NP-40). Protein homogenates were used to measure elec-
tron transport chain complexes I, III, IV, and V (ATP syn-
thase) spectrophotometrically, as previously described 
[22] and implemented by our laboratory [19, 23–26]. Pro-
tein concentrations were normalized using the Bradford 
method, with standardization to bovine serum albumin 
[27].
Citrate synthase activity
Isolated mitochondria from all 50 patients, was used to 
measure citrate synthase activity using a colorimetric 
Citrate Synthase Assay Kit (Sciencell, San Diego, CA), as 
previously described [28]. Citrate synthase activity, nor-
malized to protein content, was used to determine mito-
chondrial content.
Methyltransferase
Using a colorimetric Methyltransferase Assay Kit (Cay-
men, Ann Arbor, Michigan), S-adenosylmethionine 
(SAM)-dependent methyltransferase activity was 
assessed, per manufacturer’s instructions. Briefly, nuclear 
homogenates were used to assess total SAM-dependent 
methyltransferase activity in all 50 patients.
DNA 5mC and 5hmC quantification
Using a DNeasy Blood & Tissue Kit (Qiagen, Hilden, 
Germany), DNA was isolated from both 10 mg of atrial 
appendage tissue and mitochondria, per manufac-
turer’s instructions. Levels of 5-methylcytosine (5mC) 
and 5-hydroxymethylcytosine (5hmC) were measured 
through a 5mC and 5hmC ELISA Kit (Zymo Research, 
Irvine, CA), per manufacturer’s instructions. DNA was 
quantified using a NanoDrop™ 1000 Spectrophotometer 
(Thermo Fisher, Waltham, MA). 100  ng of nuclear (tis-
sue extract) and mitochondrial DNA were used to assess 
total 5mC and 5hmC content spectrophotometrically for 
all 50 patients.
Western blotting
Using 4–12% gradient gels, immunoblotting was per-
formed through MES SDS-PAGE, as previously 
described [21, 26, 29–31]. Protein was normalized using 
the Bradford method. Primary antibodies used in the 
study included: anti-TFAM, transcription factor A, mito-
chondrial, 1:500 (SCBT, Dallas, TX), anti-GAPDH 1:1000 
(Abcam, Cambridge, MA). The secondary antibody used 
in the study was a goat anti-mouse IgG (H&L) horse-
radish peroxidase (HRP) conjugate 1:10,000 (Thermo 
Fisher). GAPDH expression was used to normalize 
protein content. Chemiluminescence was measured 
through Radiance Chemiluminescent Substrate (Azure 
Table 1 Patient characteristics and  demographic 
information
Groups are considered significantly different if P ≤ 0.05 = * compared to non-
diabetic. All data are presented as the mean ± standard error of the mean (SEM)
HbA1c: glycated hemoglobin
Parameter Non-diabetic Type 2 diabetic
Age 61.97 ± 2.449 61.16 ± 3.047
Sex Male = 26, female = 4 Male = 15, female = 5
BMI (kg/m2) 29.13 ± 1.08 29.14 ± 1.448
Coronary artery disease 73.33% ± 8.212% 100% ± 0.0%*
Hypertension 86.67% ± 6.312% 94.74% ± 5.263%
Valvular disease 26.67% ± 8.212% 15.79% ± 8.595%
HbA1c 5.567 ± 0.07898 8.016 ± 0.4024*
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Biosystems, Dublin, CA), per manufacturer’s instruc-
tions and imaged using the G:Box Bioimaging system 
(Syngene, Frederick, MD). Images were captured through 
GeneSnap/GeneTools software (Syngene). Densitom-
etry was analyzed using ImageJ and Fiji Software (NIH, 
Bethesda, MD). Data is represented as optical density 
with arbitrary units.
Chromatin immunoprecipitation (ChIP)-qPCR
The  SimpleChIP® Plus Sonication Chromatin IP Kit 
(Cell Signaling Technology, Danvers, MA) was used, per 
manufacturer’s instructions. Briefly, 100 mg of atrial tis-
sue was minced into ~ 2  mm3 pieces and treated with 
freshly prepared 37% formaldehyde for 30 min. Sonicated 
DNA was assessed for sheering and further immunopre-
cipitated with anti-TFAM (SCBT) bound Protein G mag-
netic beads overnight at 4  °C. The beads were washed, 
DNA reverse cross-linked, and DNA eluted as previously 
described [24, 32]. DNA bound to TFAM was further 
examined through qPCR. 2% chromatin inputs for each 
sample were used for normalization of expression. An 
Applied Biosystems 7900HT Fast Real-Time PCR system 
(Applied Biosystems, Foster City, CA) was used to assess 
expression through SYBR Green. Quantification was 
achieved using the  2−ΔΔCT method [33]. All primer pairs 
to assess the mitochondrial D-Loop are provided (Addi-
tional file 1: Table S2).
Overhang-bisulfite sequencing
DNA was extracted from patient tissue as described 
above. DNA was bisulfite-treated using the EZ DNA 
Methylation-Lightning Kit (Zymo Research), per manu-
facturer’s instructions. Primers were designed for the 
CpG island of TFAM; primer set 1 amplified the 3′ end 
and primer set 2 amplified the 5′ end of the CpG island 
(Additional file 1: Table S2). Bisulfite DNA was prepared 
for sequencing using a 2-Step PCR amplification process 
[34]. Step-1 PCR adapters included a base pairing region 
(~ 23 bp) and an overhang Illumina adapter arm (~ 33 bp). 
Bisulfite DNA was PCR amplified using Step-1 prim-
ers utilizing Platinum™ Taq DNA Polymerase (Thermo 
Fisher), run on 2% agarose gels, extracted through a 
QIAquick Gel Extraction Kit (Qiagen), and DNA puri-
fied. DNA was then further amplified using Step-2 Illu-
mina barcoded adapters and prepared using a 300-cycle 
MiSeq Reagent Micro Kit v2 (Illumina, San Diego, CA). 
PCR amplicons were sequenced on the MiSeq with 
paired-end (PE) 250 base pair reads. Files were aligned 
to the bisulfite converted reference genome GRCh38 
release 94 implementing Bismark [35, 36]. Alignment was 
obtained through Bismark using the Bowtie2 [37] engine 
using “non-directional” and “paired-end.” Complete 
sequencing code is provided (https ://githu b.com/qahat 
haway /WVU_Machi ne-Learn ing-50/tree/maste r).
Mitochondrial SNP sequencing
Mitochondrial DNA was isolated as described above and 
further amplified using the REPLI-g Mitochondrial DNA 
Kit (Qiagen), per manufacturer’s instructions. Librar-
ies for amplified DNA were prepared using the MiSeq 
Reagent Kit v3 (Illumina). Mitochondrial DNA was 
sequenced on the MiSeq with paired-end (PE) 300 base 
pair reads. Files were aligned to the reference genome 
GRCh38 release 94 through Bowtie2 using “sensitive-
local.” BAM files were sorted, run through variant calling, 
and single-nucleotide polymorphisms (SNPs) were iden-
tified in the mitochondria through SAMtools [38–40]. 
Complete sequencing code is provided (https ://githu 
b.com/qahat haway /WVU_Machi ne-Learn ing-50/tree/
maste r).
Machine-learning algorithms
Decision tree classifier algorithms were created in python 
(v3.6.5) using scikit-learn [41] and pandas [42] librar-
ies (Fig.  1a). In binary classification, patient labels were 
determined through previous clinical diagnoses, where 
diabetic status was retained even if current HbA1c levels 
were below 6.5%. In multiple classification, patients with 
an HbA1c value in the range of 5.7% to 6.4% were desig-
nated as having prediabetes. Due to this, the HbA1c fea-
ture was excluded from all tested trials, and the derived 
accuracies are in comparison to that of the “perfect” 
accuracy obtained from HbA1c classification. A decision 
tree classifier model was created using the functions of 
scikit-learn tree. The data file was split into 80% train-
ing and 20% testing partitions using a defined seed value. 
Different seeds were chosen for each set to maintain the 
training and testing set distributions. Selected seed val-
ues maintained a binary classification testing set of five 
diabetics and five non-diabetics. In the multiple classifi-
cation testing set, seed values maintained a distribution 
of three diabetics, three non-diabetics, and four pre-
diabetics. Seeds were only chosen such that the result-
ing training and testing accuracies were similar; ensuring 
that the created classification tree did not over fit to the 
small sample size and remained generalizable to future 
testing samples.
Within the model, tenfold cross validation was 
implemented. CART analysis was then performed on 
each of the datasets using the scikit-learn model, and 
the features of importance extracted using the feature 
importance parameter. The physiological/biochemical, 
genomic, and epigenomic datasets were combined into 
a single file to serve as the “all features” dataset used 
to extract the best and most influential biomarkers. 
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For each trial, selected combinations of biomarkers 
from each dataset were utilized, and within each trial 
CART analysis was performed five times. After each of 
the five iterations, average feature importance, average 
training, and average testing accuracies were obtained. 
Standard deviations were taken over each of the five 
iterations per trial. For each dataset, the first iteration 
of CART analysis included all biomarkers of each set. 
If the average feature importance was less than 1%, the 
feature was no longer included in subsequent trials. 
After all iterations, if the average feature importance 
was less than or equal to 8% it was assigned to a cate-
gory titled “other.” These same trials were repeated with 
other default scikit-learn machine-learning frameworks 
(Logistic Regression, Linear Discriminant Analysis, 
K-Nearest Neighbors Classifier, Gaussian Naïve Bayes, 
and Support Vector Machine). Tenfold cross validation 
and the same seed parameters were used in analysis of 
these five models and the resulting training and testing 
accuracies are provided (Additional file  1: Tables S3–
S10). The six models tested include few modifications 
and utilize no additional regularization techniques 
aside from those default to the scikit-learn library mod-
els. Only the Support Vector Machine model received 
modifications, with the probability parameter set to 
“true” to provide probability estimates for each data 
point and a linear kernel used over the default Radial 
Basis Function ‘rbf ’ kernel. Code for analyses is also 
provided (https ://githu b.com/qahat haway /WVU_
Machi ne-Learn ing-50/tree/maste r).
Machine-learning feature extraction and accuracy
To determine which model(s) would provide the most 
accurate predictions on the current data, we assessed the 
345 total features across all six models in binary (Table 2) 
and multiple (Table  3) classification of diabetic status. 
Through assessment of individual datasets (i.e. physi-
ological/biochemical, genetic, and epigenetic), a set of 
18 features was further used to classify diabetic status in 
binary (Additional file 1: Table S11) and multiple (Addi-
tional file 1: Table S12) classification. Model analysis was 
enacted for each dataset, and the established tenfold 
cross validation and seed parameters for binary and mul-
tiple classification were utilized. Each dataset was tested 
five times per model. Averages were obtained for train-
ing accuracy, training standard deviation, testing accu-
racy, testing standard deviation, model average F1 score, 
and area under the curve (AUC). AUC values were pro-
vided for each of the six tested algorithms for the testing 
data under binary classification using the roc_auc_score 
function of scikit-learn, but not for multiple classifica-
tion. AUC was determined as 1.0 for LR and SVM mod-
els when evaluating the 345 total features due to the 
large sample size of biomarkers. From the available 345 
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Fig. 1 Overview of machine-learning using Classification and Regression Trees (CART) and SHapley Additive exPlanations (SHAP). a Classification 
trees begin with a specific parameter that most successfully partitions the samples, such as CpG24 methylation, and determine the probability of 
correctly delineating a population into classifications, such as non-diabetic and diabetic, through a discrete value of the parameter (e.g. 0.275). The 
delineation is then given a probability score (i.e. 0.475, or a 47.5% chance of classifying the sample incorrectly), assigned a label, and further passed 
on to other parameters in the tree (e.g. CpG11 methylation and CpG28 methylation). As the samples progress through the tiers of the tree, the Gini 
impurity gets smaller, more accurately delineating samples that make it to that particular “truth” statement. b An example of how SHAP illustrates 
sample distribution. The “SHAP Value” delineates between a condition being true (value > 0.0, T2DM) and it being false (value < 0.0, ND). The more 
a specific value of a sample influences the composition of the model, the farther the point will migrate away from zero on the y-axis. If the value 
of a sample does not influence the model, it will reside near or at zero on the y-axis. In the example, a larger value of “X” and lower value of “Z” are 
highly predictive of the patient being ND, with these values strongly influencing the model “Y”. CpG: cytosine nucleotide followed by a guanine 
nucleotide; ND: non-diabetic; T2DM: type 2 diabetic
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features, two predictors were chosen that perfectly dis-
tinguished diabetic and nondiabetic status for this par-
ticular dataset. As such, these AUC values were removed 
from Table 2 for LR and SVM, as this was not an accu-
rate indicator of the model’s predictive ability. As the 
feature set was restricted to the 18 “best” features from 
Table 2 Overview of 6 machine-learning model analysis on all 345 features in binary classification
Model analysis was conducted five times and averages are reported for the resulting training accuracy, training standard deviation, testing accuracy, testing standard 
deviation, F1 score, and area under the curve (AUC). Important biomarker features associated with each trained model are provided along with the associated 
influence value for each feature. Important features are listed in order of influence within the model. LR, LDA, SVM feature bias exists as an influence parameter where 
magnitude dictates feature influence. A positive influence value indicates the biomarker favors classification towards one label while a negative value indicates 
favorable classification of the opposite label. The larger the magnitude, the more strongly that feature shifts classification. NB feature influence indicates the most 
important biomarker per class in binary (0,1) classification schemes. CART feature bias percentages indicate feature influence on the created classification tree. Larger 
percentages indicate a feature that arises near the beginning of a tree before subsequent branching. Influence is not provided for KNN due to model restrictions
Model Training Training (StDev) Testing Testing 
(StDev)
F1 score Important features Important feature bias AUC 
LR 0.608 0.301 0.667 0.0 0.640 Complex III, Complex I, CpG31, 
CpG28, CpG30, Complex IV, CpG8, 
CpG4, CpG12, Age
(− 2.688), (− 1.688), (1.648), 
(− 1.163), (− 1.016), (0.982), 
(0.945), (0.887), (0.882), (0.848)
NA
LDA 0.567 0.203 0.556 0.0 0.400 SNP16245, SNP16344, SNP151, 
SNP5463, SNP4295, SNP13722, 
SNP94, SNP15884, SNP9055, 
SNP477
(− 3.896E+15), (− 3.896E+15), 
(− 3.896E+15), (− 3.896E+15), 
(− 2.719E+15), (− 2.719E+15), 
(3.398E+14), (3.398E+14), 
(3.398E+14), 0.266
0.700
KNN 0.642 0.239 0.444 0.0 0.430 NA NA 0.600
NB 0.725 0.227 0.778 0.0 0.780 Mito 5hmC, Methyltransferase (1.000), (0.000) 0.775
SVM 0.583 0.337 0.667 0.0 0.640 Complex III, CpG31, Complex I, 
CpG28, CpG8, CpG22, CpG12, 
CpG29, CpG4, CpG35
(− 0.732), (0.488), (− 0.443), 
(− 0.372), (0.350), (− 0.349), 
(0.322), (− 0.260), (0.259), (0.257)
NA
CART 0.790 0.209 0.711 0.1 0.714 CpG 24, CpG 28, Nuc 5mC, CpG11, 
CpG23, CpG1, CpG4
(0.587%), (0.213%), (0.040%), 
(0.040%), (0.040%), (0.040%), 
(0.040%)
0.715
Table 3 Overview of 6 machine-learning model analysis on all 345 features in multiple classification
Model analysis was conducted five times and averages are reported for the resulting training accuracy, training standard deviation, testing accuracy, testing standard 
deviation, and F1 score. Important biomarker features associated with each trained model are provided along with the associated influence value for each feature. 
Important features are listed in order of influence within the model. LR, LDA, SVM feature bias exists as an influence parameter where magnitude dictates feature 
influence. A positive influence value indicates the biomarker favors classification towards one label while a negative value indicates favorable classification of the 
opposite label. The larger the magnitude, the more strongly that feature shifts classification. NB feature influence indicates the most important biomarker per class 
in multiple (0,1,2) classification schemes. CART feature bias percentages indicate feature influence on the created classification tree. Larger percentages indicate a 
feature that arises near the beginning of a tree before subsequent branching. Influence is not provided for KNN due to model restrictions
Model Training Training (StDev) Testing Testing 
(StDev)
F1 score Important features Important feature bias
LR 0.333 0.207 0.444 0.0 0.430 Complex V, CpG35, BMI, CpG38, 
CpG18, CpG40, CpG19, CpG23, 
Complex IV, CpG25
(− 2.417), (− 2.214), (1.942), (− 1.541), 
(− 1.313), (− 0.994), (− 0.881), 
(− 0.824), (− 0.812), (0.8071)
LDA 0.433 0.178 0.333 0.0 0.170 SNP11167, SNP10506, SNP16309, 
SNP16343, SNP2294, SNP14139, 
SNP16162, SNP3672, SNP8642, 
SNP143
(− 4.623E+14), (− 4.623E+14), 
(− 4.623E+14), (− 4.623E+14), 
(− 4.623E+14), (− 4.623E+14), 
(− 4.623E+14), (− 4.623E+14), 
(− 4.623E+14), (5.779E+13)
KNN 0.358 0.239 0.444 0.0 0.450 NA NA
NB 0.425 0.243 0.778 0.0 0.780 Methyltransferase, Mito 5hmC, Nuc 5 
hmC
(0.000), (1.000), (2.000)
SVM 0.442 0.163 0.556 0.0 0.520 Complex V, BMI, Complex III, Complex 
I, Complex IV, CpG31, Age, CpG19, 
CpG22, CpG6
(− 0.943), (0.754), (0.561), (− 0.383), 
(− 0.344), (0.307), (− 0.287), 
(− 0.268), (− 0.210), (0.198)
CART 0.660 0.257 0.556 0.0 0.558 CpG24, TFAM CpG, TFAM Non-CpG, 
BMI, SNP94, Complex IV, SNP8557, 
CpG7, SNP242, SNP13722, Complex 
III, Mito 5mC
(0.328%), (0.206%), (0.176%), (0.137%), 
(0.016%), (0.045%), (0.016%), 
(0.016%), (0.016%), (0.016%), 
(0.016%), (0.016%)
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each dataset, AUC values of 1.0 were no longer observed 
(Additional file 1: Tables S11 and S12). 
Extracted important features and corresponding fea-
ture bias within each model, with the exception of 
KNN, were determined and are provided for binary 
and multiple classification. CART feature importance 
was extracted from the trained model using the feature 
importance parameter. For the NB model, feature influ-
ence was determined using the predict_log_proba func-
tion to return the most important biomarker per class 
in both binary (0,1) and multiple (0,1,2) classification 
schemes. Feature importance was not determined for 
the KNN model due to the restrictions of the default 
model. LDA, LR, and SVM feature influence was deter-
mined by taking the magnitude of the model coeffi-
cients, coef_ parameter, times the standard deviation of 
that biomarker in the testing data. The resulting values 
are ranked based off magnitude and are reported with 
sign under the “Important Feature Bias” (Tables 2 and 3, 
Additional file  1: Tables S11 and S12). A positive influ-
ence value indicates a biomarker favoring classification 
towards one label while a negative value favors the oppo-
site classification label. The larger the magnitude, the 
more strongly that feature shifts classification.
SHapley Additive exPlanations (SHAP)
SHAP framework, from slundberg (https ://githu b.com/
slund berg/shap), was used to visually explain the classi-
fication trees developed for the 50 patient samples using 
an XGBoost model (Fig. 1b) [43–45]. Figure 1b illustrates 
how SHAP plots are presented in three dimensions, with 
the “X” and “Y” dimensions plotted spatially while the 
“Z” dimension is indicated only through color; allow-
ing for the examination of how variables, “X” and “Z”, 
can influence the nature of the model and classification 
of patients, “Y”, into non-diabetic and diabetic cohorts. 
Through Jupyter Notebook (v0.34.9) [46] with a Python 
3 kernel and importing pandas, shap, and xgboost librar-
ies, SHAP plots were derived. Delineation of binary and 
multiple classification systems are defined above. The 
entire 50 patient population was utilized during training 
of the XGBoost model and both the patient biomarker 
values and patient labels were provided during training. 
The XGBoost and SHAP tree explainer utilized were left 
unaltered. The number of influential features shown in 
the summary plot were selected using the max display 
parameter. Plot generation utilized force plot, depend-
ency plot, and summary plot SHAP functions. Force 
plots depict the effect of biomarker values on the model’s 
output. Dependency plots relate specific biomarker val-
ues to model prediction and show how the chosen bio-
marker depends on other tested biomarkers. Summary 
plots depict the top influential biomarkers and how they 
influence the model prediction. Code for analyses is also 
provided (https ://githu b.com/qahat haway /WVU_Machi 
ne-Learn ing-50/tree/maste r).
Statistics
Significance was determined using a two-tailed Stu-
dent’s t-test or one-way analysis of variance (ANOVA), 
where appropriate. Tukey’s multiple comparisons test 
was implemented following the ANOVA to derive sig-
nificance between multiple groups. Differences between 
groups were considered statistically different if P ≤ 0.05, 
denoted by * if statistically different from non-diabetic 
or # if statistically different from pre-diabetic. All data 
are presented as the mean ± standard error of the mean 
(SEM).
Data availability
Mitochondrial DNA-Seq: Sequence Read Archive 
PRJNA520920 https ://datav iew.ncbi.nlm.nih.gov/?searc 
h=SUB51 24294 .
TFAM Promoter Methylation Amplicon-Seq: Sequence 
Read Archive PRJNA520920 https ://datav iew.ncbi.nlm.
nih.gov/?searc h=SUB51 25264 .
Bioinformatics and Machine-learning Scripts: Github 
https ://githu b.com/qahat haway /WVU_Machi ne-Learn 
ing-50/tree/maste r.
Results
Alterations to the interaction networks that exist between 
the nucleus and mitochondrion play a significant role in 
the development of diabetic cardiomyopathy [47–50]. As 
a result, we wanted to determine how observed changes 
in these parameters could predict diabetic status using 
machine-learning algorithms. All of the machine-learn-
ing algorithms in this study implemented to draw con-
clusions were constructed around tree ensembles, such 
as Classification and Regression Trees (CART). CART 
algorithms proved to have the overall highest testing 
and training accuracies when compared to other models 
(Additional file  1: Tables S3–S10), while also perform-
ing superiorly in multiple classification of prediabetes 
(Tables 2, 3). When examining the testing, training, and 
area under the curve (AUC) values that depict model 
performance, CART performed consistently at, or near, 
the top of the six models in both the binary (Table  2) 
and multiple (Table 3) classification sets when assessing 
all 345 features. SHapley Additive exPlanations (SHAP) 
which implement CART functions were used to pro-
vide binary (non-diabetic or type 2 diabetic) as well as 
multiple (non-diabetic, prediabetic, and type 2 diabetic) 
classification analyses. SHAP analysis maps a particular 
biomarker’s numeric values to a computationally defined 
SHAP value that represents the degree to which specific 
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biomarker values classify the patient to a particular label 
(non-diabetic or type 2 diabetic). We wanted to demon-
strate how machine-learning algorithms, applied across 
a variety of health outcome datasets, could be imple-
mented to identify novel biomarkers, with and without 
HbA1c, to provide better assessment of type 2 diabetes 
mellitus. By presenting each dataset distinctly, we were 
able to assess which biomarkers provided the best overall 
predictive power.
Physiological and biochemical analyses
Those with type 2 diabetes mellitus had significantly 
lower electron transport chain (ETC) complex I and 
III activities, along with a decreased methyltransferase 
activity (Additional file 1: Table S13). Using CART analy-
sis and machine-learning, total nuclear methylation, total 
mitochondrial hydroxymethylation, and total nuclear 
hydroxymethylation were shown to be the most impor-
tant factors influencing the model (Fig. 2a). Total nuclear 
methylation was also shown to be significantly increased 
in type 2 diabetics (Fig.  2b) with a corresponding 
decrease in total nuclear hydroxymethylation (Fig.  2c). 
Nuclear methylation increased as HbA1c levels increased 
(Fig. 2d) while the rate of hydroxymethylation, generally 
inversely correlated with methylation levels, decreased 
as HbA1c increased (Fig. 2e). Methyltransferase activity, 
total mitochondrial hydroxymethylation, total nuclear 
methylation, and total nuclear hydroxymethylation were 
shown to be important features in predicting type 2 dia-
betes mellitus in the absence of HbA1c (Fig.  2f ). High 
s-adenosyl methionine (SAM) methyltransferase activ-
ity was also shown to be strongly associated with lower 
total nuclear methylation levels in the absence of HbA1c 
(Fig. 2g).
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A decrease in mitochondrial ETC complex III activ-
ity was associated with a higher BMI (Fig.  2h). While 
those who were considered to be prediabetic (HbA1c 
5.7–6.4) did not show significant differences between any 
of the biochemical measures except total TFAM CpG 
methylation (Additional file  1: Table  S14), total nuclear 
methylation was still shown to provide partial classifica-
tion of patients into non-diabetic, prediabetic, and type 
2 diabetic designations (Fig.  2i, j). CART tenfold cross 
validation confirmed findings for binary [testing (0.838), 
training (0.7448)] and multiple [testing (0.598), training 
(0.545)] classification (Additional file 1: Figure S1A–D).
Genomic analyses
The complete mitochondrial genomes of all patients 
were sequenced, and a list of all single nucleotide poly-
morphisms (SNPs) was compiled. The binary nature 
of SNPs, i.e. either being converted or not, allowed the 
dynamic HbA1c levels to influence the machine-learn-
ing model much more efficiently (Fig. 3a). When HbA1c 
was removed, classification of diabetic or non-diabetic 
through SNPs was much more apparent, revealing that 
the 16,362 base pair was most significantly impacted 
(Fig.  3b). When examining the distribution of SNPs 
across the mitochondrial genome, the most significant 
area for base pair alterations to occur was shown to be 
the D-Loop, or control region (Fig. 3c).
The D-Loop (mtDNA 16,025–576 bp), as compared to 
all other regions in the mitochondrial genome, contained 
the highest frequency of SNPs used to predict type 2 dia-
betes mellitus (Fig. 3a, b, Additional file 1: Figure S2A, B). 
We further investigated how transcription factor bind-
ing could be altered at the D-Loop through chromatin 
immunoprecipitation (ChIP) of mitochondrial transcrip-
tion factor A, mitochondrial (TFAM). Though protein 
levels of TFAM were unchanged (Additional file 1: Figure 
S3A), ChIP-qPCR revealed decreased binding of TFAM 
to the proximal and distal end of the control region in 
type 2 diabetics (Additional file 1: Figure S3B). SNPs near 
the replication of the H strand (Fig. 3d) or at the end of 
the D-Loop region (Fig. 3e) could impact TFAM binding 
and mitochondrial genome transcription. CART tenfold 
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cross validation confirmed findings for binary [testing 
(0.79), training (0.92)] and multiple [testing (0.576), 
training (0.808)] classification (Additional file  1: Figure 
S2A–D).
Epigenomic analyses
The cytosine nucleotide followed by a guanine nucleo-
tide (CpG) island of TFAM was examined (Fig. 4a), using 
overhang bisulfite PCR to amplify regions of the island 
for sequencing (Fig. 4b). Though total methylation of the 
gene was low (~ 3%) and showed no significant differ-
ences between non-diabetic and type 2 diabetic patients 
(Additional file  1: Table  S13), site-specific CpG island 
methylation changes revealed significant differences 
between groups (Fig. 4a). Specifically, the 24th (CpG24) 
and 29th (CpG29) CpGs in the amplified region revealed 
significant hypomethylation in type 2 diabetic patients 
(Fig. 4c, d).
Without using the HbA1c parameter, methylation lev-
els at CpG24, 1, 29, and 35 were shown to be significant 
contributors to the prediction of diabetic status (Fig. 4e). 
When comparing the interactions of CpG24 and CpG29, 
methylation levels at CpG24 were shown to allow distinct 
separation of the non-diabetic and type 2 diabetic popu-
lation (Fig. 4f ). CpG24 methylation remained a primary 
predictor, even in the presence of HbA1c for multiple 
classification (Fig.  4g). Examining total methylation of 
the TFAM CpG island, prediabetics exhibited an overall 
increase in methylation, while non-diabetics and type 2 
diabetics with similar HbA1c levels showed much lower 
expression (Fig. 4h). CART tenfold cross validation con-
firmed findings for binary [testing (0.79), training (0.925)] 
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and multiple [testing (0.668), training (0.767)] classifica-
tion (Additional file 1: Figure S4A–D).
Best/combined analyses
Those physiological, biochemical, genomic, and/or epig-
enomic markers that provided the best association within 
their class for predicting type 2 diabetes mellitus status 
were used in the final analyses. With the combined list of 
features, CART algorithms continued to perform consist-
ently at, or near, the top for testing and training accura-
cies in binary (Additional file 1: Table S11) and multiple 
(Additional file 1: Table S12) classification. Total nuclear 
hydroxymethylation and total nuclear methylation lev-
els provided the most powerful predictors in delineat-
ing between binary (non-diabetic and type 2 diabetic) 
(Fig.  5a) and multiple (non-diabetic, prediabetic, type 2 
diabetic) (Fig.  5b) classifications, distinguishing them as 
potentially suitable biomarkers to accompany diagnostic 
practices using HbA1c. When using machine-learning to 
predict diabetic status without HbA1c, CpG24 methyla-
tion status and total nuclear methylation proved to be the 
most powerful predictors in both the binary (Fig. 5c) and 
multiple (Fig. 5d) classification datasets. Ultimately, both 
in the prediction of type 2 diabetes mellitus (Fig. 5e) and 
in assessing the onset (Fig. 5f ), CpG24 hypomethylation 
was strongly correlated with total nuclear hypermethyla-
tion. CART tenfold cross validation confirmed findings 
for binary [testing (0.78), training (0.832)] and multiple 
[testing (0.67), training (0.542)] classification (Additional 
file 1: Figure S5A–D). Within our datasets, CpG24 meth-
ylation status and total nuclear methylation provided the 
best predictive measures for assessing type 2 diabetes 
mellitus. The incorporation of physiological, biochemical, 
genetic, and epigenetic features with machine-learning 
algorithms exemplifies the potential for more informa-
tive diagnostics in the future, as well as personalized 
approaches to generalized treatment modalities (Fig. 6). 
Discussion
Machine-learning can be applied as a systems biol-
ogy approach, integrating multiple classes of biometric 
data to assess the importance of specific factors, while 
also predicting future outcomes. Whereas conventional 
assessments of disease identification exist, more detailed 
genomic and epigenomic testing is likely to reveal a com-
prehensive, systemic valuation of an etiology. To-date, 
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studies have applied machine-learning algorithms in 
examining the physiological, biochemical, and/or genetic 
components of disease onset or progression [51]. The 
advantage of our current study is through the assimila-
tion of patient-matched data across a variety of critically 
impacted systems, providing an archetype for devel-
oping novel, descriptive, diagnostic measures through 
machine-learning algorithms that are specific for each 
disease type. By individually representing our datasets in 
Figs.  2, 3 and 4, we were able to reach more conclusive 
data in Fig.  5 by choosing the most predictive features 
for our final model. For the first time, a multi-omics, 
machine-learning approach was used to assess the pro-
gression and development of type 2 diabetes mellitus in 
a patient population, identifying potential biomarkers for 
cardiovascular risk and revealing the fundamental role of 
genetics in the pathology.
Molecular pathogenesis and machine-learning
While clinical practice has recently experienced a surge 
in deep learning applications used for non-invasive imag-
ing [52], implementing machine-learning algorithms to 
the fundamental biochemistry and cellular and molecu-
lar processes of the body is now only blossoming. Onset 
and progression of type 2 diabetes has been traditionally 
measured through blood glucose levels, but, the mul-
tifaceted aspects of the disease could create variability 
in prognosis between vastly different demographic and 
ethnic groups. Owusu Adjah et  al. [14] recently identi-
fied BMI as a risk factor for determining ethnic group 
disposition to type 2 diabetes mellitus. Specifically, the 
relationship between BMI and increased incidence of 
diabetes mellitus is non-linear; some groups, such as 
South Asian populations, were more disposed to devel-
oping the disease even at lower BMIs. While the current 
Fig. 6 Overview of machine-learning pipeline implementing biological variables across a spectrum of gathered information. From the patient 
population undergoing coronary artery bypass graft surgery (CABG), physiological parameters (demographics, health reports, etc.) and atrial 
tissue were used for subsequent analyses. From cardiac tissue genomic (mitochondrial DNA), epigenomic (TFAM promoter CpG methylation), and 
biochemical (nuclear and mitochondrial function) were assessed. Cumulatively, the biological data was processed through tree ensembles in SHAP 
and validated through CART analysis with tenfold cross validation. Using these machine-learning algorithms, graphical depictions and biomarker 
feature importance are able to be derived, allowing for prediction of the onset and progression of diabetes. Ultimately, by using biological data 
at the genomic and epigenomic level, it allows for precision medicine approaches and more personalized diagnostics and prognostics. TFAM: 
transcription factor A, mitochondrial; mtDNA: mitochondrial DNA; CpG: cytosine nucleotide followed by a guanine nucleotide; CART: Classification 
and Regression Trees; SHAP: SHapley Additive exPlanations
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manuscript examines cardiovascular tissue, other less 
invasive approaches have been used to apply machine-
learning algorithms. By retrieving blood from the basilica 
vein, circulating biomarkers were examined for their role 
in predicting early recurrence of atrial fibrillation follow-
ing cryoballoon ablation [53]. Support vector machines 
confirmed that decreased levels of creatine-kinase 
(CK-MB) and Troponin T (TnT) were associated with 
increased early recurrence of atrial fibrillation following 
cryoballoon ablation. Additionally, a unique, non-inva-
sive approach for potentially diagnosing type 2 diabetes 
in patients was performed through the examination of 
toenails. Carter et al. [54], through a variety of machine 
learning algorithms, focused on 22 elements, including 
aluminum, cesium, nickel, vanadium, and zinc, and was 
able to get an AUC of 0.90 when predicting diabetic sta-
tus using a random forest model.
Similar to parts of the aims of this study, other groups 
have attempted to use machine learning to separate dia-
betic and non-diabetic patients without the inclusion of 
blood glucose or HbA1c [55]. In a testing set of 13,700 
patients from the Luzhou, China region, random forest 
machine-learning algorithms provided a 0.7225 accuracy 
when predicting diabetic status from physical examina-
tion data in the absence of blood glucose [55]. Also using 
a random forest model, Tang et  al. [56] revealed how 
CpG island methylation data, combined with microRNA 
expression profiles, can be instrumental in cancer patho-
genesis; implementing this two-feature selection process, 
they were able to identify the best tissue specific features, 
ultimately allowing for the identification of the originat-
ing tissue where tumor progression began. In a similar 
fashion, the machine-learning algorithm HeteSim [57], 
which examines heterogeneous datasets and calculates 
their relatedness, was employed in ascribing how gene 
profiles can be related to phenotypic outcomes, specifi-
cally in the validation and prediction of genes classified 
within major diseases [58].
While understanding how to better form prognoses 
and treat cardiac dysfunction in patients with type 2 dia-
betes mellitus remains a critical mission, more than 80 
million American adults, most of which are undiagnosed, 
are prediabetic [59]. In the current work, we have imple-
mented predictive algorithms to assess biomarkers likely 
involved in the onset, as well as prediabetic progression, 
of type 2 diabetes mellitus. Although multiple classifica-
tion categories further reduce the predictive power of 
the model, separation into distinct groupings revealed a 
unique phenotype for prediabetics (Fig.  4h). The effects 
of diabetes mellitus on the body is a high glucose stressed 
condition, altering substrate metabolism and causing 
systemic inflammation [60]. Due to this environmental 
change, researchers have shown how epigenetic changes 
occur across most, if not all, tissues that are impacted by 
diabetes mellitus [49, 61].
In the cardiovascular system, the heart, circulatory 
system, and regulating immune system are all tran-
scriptionally regulated through epigenetic alterations 
[48, 62], resulting in cellular adaptations to the environ-
mental stress. Examining atrial appendages, the results 
obtained in this study are a direct reflection of changes 
within the heart. While blood is more easily acquired in 
type 2 diabetic patients, cardiac tissue, which is mito-
chondrially rich, provides a direct connection between 
physiological dysfunction observed in the heart and the 
impact of altered genomic profiles in the mitochondrion 
and nucleus. Machine-learning, which at current has 
been applied to very few genetic applications, may play 
a significant role in defining the epigenome of those with 
diabetes mellitus, likely unveiling genes and molecular 
pathways first impacted by the pathology.
The challenges of machine learning in the clinical setting
Machine-learning algorithms produce generalizations 
as they are inherently predictive, which means a smaller 
sample size can occasionally result in increased emphasis 
on outliers within the patient dataset and determination 
of the outliers’ biomarker features to be most influential 
in disease diagnosis. With a limited 50 patient dataset, 
there are concerns of overfitting the model, where the 
derived classification tree would have branches for each 
patient sample encountered during training. If this was to 
occur, the produced tree would fail future test cases while 
maintaining near perfect training accuracy, which was 
not observed. Tenfold cross validation ensured that no 
single developed tree was composed solely of outliers or a 
group of patient data of one label type, allowing patients 
of different labels to train the algorithm. Additionally, 
choosing seed values provided an even patient distribu-
tion during model training and testing. Both tenfold cross 
validation and setting a seed allowed the derived models 
to not over fit the training data. With this being said, it 
should be noted that the small sample size limits the con-
clusions and predictions made by the machine-learning 
algorithms within the manuscript, and future investiga-
tions will need to validate specific features, including 
CpG24 of TFAM and global nuclear DNA methylation.
For developed frameworks and the implemented SHAP 
visualization, the results are inherently regulated by 
HbA1c since patient HbA1c values were used to assign 
the labels from which the machine-learning algorithm 
then proceeded to train. HbA1c is used as a guide in this 
study to help clarify how clinically assessed progression 
of diabetes (commonly through HbA1c levels) is related 
to the biochemical and genetic signatures found in the 
heart. Although no specific biomarker or biomarker 
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combinations can replace HbA1c due to the apparent 
diagnostic bias in this study (essentially ~ 100% accuracy 
when included), they can provide predictive accuracies 
near that of HbA1c. While previous clinical diagno-
ses determined a patients’ diabetic status in this study, 
some patients diagnosed as type 2 diabetics had HbA1c 
levels within normal ranges; begging the question of 
whether sustained, or attenuated, health effects can be 
accurately assessed through HbA1c levels alone when 
intervention (lifestyle or medicinally) occurs? Ultimately, 
this study provides a machine-learning algorithm utiliz-
ing the respective advantages of HbA1c in combination 
with other biomarkers to help circumvent the limita-
tions of modern HbA1c diagnosis, as well as introduces 
completely novel cardiac risk stratification paradigms for 
patients with type 2 diabetes mellitus.
The quantity and diversity of omics-based approaches 
continues to expand. Convenience and increasingly inex-
pensive options for biometric-based valuations incite a 
growing demand for the incorporation and meaningful 
explanation of large and diverse patient datasets. The 
methodology outlined in this manuscript can serve as an 
archetype for the development and implementation of 
machine-learning to other disciplines seeking to evaluate 
disease progression. By using various health outcomes 
datasets, we were able to identify, and combine, the most 
prominent biomarkers into an accurate predictive algo-
rithm engineered around 50 patients. While we have 
identified specific genetic features that are highly predic-
tive in 50 patients, as a much larger patient population 
is applied to this model, the prioritization of other fea-
tures is likely to occur, enhancing the diagnostic potential 
for the individual diabetic or prediabetic patient. Indeed, 
this is the advantage of using machine-learning models, 
in that they continue to learn and develop more accurate 
predictions as the number of features and sampled popu-
lation grows.
Conclusions
Our work highlights the importance of identifying bio-
markers in systems known to be disturbed during the 
disease (i.e. the mitochondrion and nucleus), and further 
applying these biological systems to personalized prog-
nostics. By implementing classification tree, machine-
learning algorithms to cardiac tissue from type 2 diabetic 
patients, we determined that hypermethylation of the 
nuclear genome was predictive of diabetic status and that 
it may provide added benefit to diagnostic applications in 
the future. Additionally, through our machine-learning 
model, as little as a ~ 5% change in methylation status of 
a gene promoter could provide valuable predictive data 
when determining diabetic status. Defining new diagnos-
tic parameters, better predicting future health outcomes, 
and specializing modalities of care begins with the inte-
gration of “big data” into machine-learning systems; this 
study reveals how integration of data assists in the deter-
mination of diabetic status in the heart.
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